People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$-0.21 (-0.55%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kulkarni, Samarth 

Dr. Samarth Kulkarni, Ph.D., is Chief Executive Officer, Director of CRISPR Therapeutics Ltd.. effective December 1, 2017. He has experience in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications. He received his Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in numerous journals.

Basic Compensation

Total Annual Compensation, USD 189,583
Restricted Stock Award, USD 277,074
Long-Term Incentive Plans, USD --
All Other, USD 984,860
Fiscal Year Total, USD 1,451,520

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --